Marlou P M Adriaanse1, Daniel A Leffler2, Ciaran P Kelly2, Detlef Schuppan2,3, Robert M Najarian4, Jeffrey D Goldsmith4, Wim A Buurman5, Anita C E Vreugdenhil1. 1. Department of Pediatrics and Nutrition and Toxicology Research Institute Maastricht (NUTRIM), Maastricht University Medical Center, Maastricht, the Netherlands. 2. Department of Gastroenterology, Celiac Disease Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. 3. Institute of Translational Immunology, Research Center of Immunology (FZI), University Medical Center, Mainz, Germany. 4. Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. 5. Department of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands.
Abstract
OBJECTIVES: Response to gluten challenge (GC) is a key feature in diagnostic algorithms and research trials in celiac disease (CD). Currently, autoantibody titers, late responders to GC, and invasive duodenal biopsies are used to evaluate gluten responsiveness. This study investigated the accuracy of serum intestinal-fatty acid binding protein (I-FABP), a marker for intestinal epithelial damage, to predict intestinal damage during GC in patients with CD. METHODS: Twenty adult CD patients in remission underwent a two-week GC with 3 or 7.5 g of gluten daily. Study visits occurred at day -14, 0, 3, 7, 14, and 28. Serum I-FABP, antibodies to tissue transglutaminase (tTG-IgA), deamidated gliadin peptides (IgA-DGP), and anti-actin (AAA-IgA) were assessed at each visit. Villous-height to crypt-depth ratio (Vh:Cd) and intraepithelial lymphocyte (IEL) count were evaluated at day -14, 3, and 14. Forty-three CD-serology negative individuals were included to compare serum I-FABP levels in CD patients on a gluten-free diet (GFD) with those in healthy subjects. RESULTS: Serum I-FABP levels increased significantly during a two-week GC. In contrast, the most pronounced autoantibody increase was found at day 28, when patients had already returned to a GFD for two weeks. IgA-AAA titers were only significantly elevated at day 28. I-FABP levels and IEL count correlated at baseline (r=0.458, P=0.042) and at day 14 (r=0.654, P=0.002) of GC. Neither gluten dose nor time on a GFD influenced I-FABP change during GC. CONCLUSIONS: Serum I-FABP levels increased significantly during a two-week GC in adult CD patients and correlated with IEL count. The data suggest that serum I-FABP is an early marker of gluten-induced enteropathy in celiac patients and may be of use in both clinical and research settings.
OBJECTIVES: Response to gluten challenge (GC) is a key feature in diagnostic algorithms and research trials in celiac disease (CD). Currently, autoantibody titers, late responders to GC, and invasive duodenal biopsies are used to evaluate gluten responsiveness. This study investigated the accuracy of serum intestinal-fatty acid binding protein (I-FABP), a marker for intestinal epithelial damage, to predict intestinal damage during GC in patients with CD. METHODS: Twenty adult CDpatients in remission underwent a two-week GC with 3 or 7.5 g of gluten daily. Study visits occurred at day -14, 0, 3, 7, 14, and 28. Serum I-FABP, antibodies to tissue transglutaminase (tTG-IgA), deamidated gliadin peptides (IgA-DGP), and anti-actin (AAA-IgA) were assessed at each visit. Villous-height to crypt-depth ratio (Vh:Cd) and intraepithelial lymphocyte (IEL) count were evaluated at day -14, 3, and 14. Forty-three CD-serology negative individuals were included to compare serum I-FABP levels in CDpatients on a gluten-free diet (GFD) with those in healthy subjects. RESULTS: Serum I-FABP levels increased significantly during a two-week GC. In contrast, the most pronounced autoantibody increase was found at day 28, when patients had already returned to a GFD for two weeks. IgA-AAA titers were only significantly elevated at day 28. I-FABP levels and IEL count correlated at baseline (r=0.458, P=0.042) and at day 14 (r=0.654, P=0.002) of GC. Neither gluten dose nor time on a GFD influenced I-FABP change during GC. CONCLUSIONS: Serum I-FABP levels increased significantly during a two-week GC in adult CDpatients and correlated with IEL count. The data suggest that serum I-FABP is an early marker of gluten-induced enteropathy in celiac patients and may be of use in both clinical and research settings.
Authors: C P Kelly; P H R Green; J A Murray; A Dimarino; A Colatrella; D A Leffler; T Alexander; R Arsenescu; F Leon; J G Jiang; L A Arterburn; B M Paterson; R N Fedorak Journal: Aliment Pharmacol Ther Date: 2012-11-19 Impact factor: 8.171
Authors: D A Leffler; J B Edwards George; M Dennis; E F Cook; D Schuppan; C P Kelly Journal: Aliment Pharmacol Ther Date: 2007-11-01 Impact factor: 8.171
Authors: Daniel A Leffler; C P Kelly; H Z Abdallah; A M Colatrella; L A Harris; F Leon; L A Arterburn; B M Paterson; Z H Lan; J A Murray Journal: Am J Gastroenterol Date: 2012-07-24 Impact factor: 10.864
Authors: D Yablecovitch; A Oren; S Ben-Horin; E Fudim; R Eliakim; T Saker; F M Konikoff; U Kopylov; T Matthias; A Lerner Journal: Dig Dis Sci Date: 2016-12-26 Impact factor: 3.199
Authors: Michelle S Lau; Peter D Mooney; William L White; Michael A Rees; Simon H Wong; Matthew Kurien; Nick Trott; Daniel A Leffler; Marios Hadjivassiliou; David S Sanders Journal: Am J Gastroenterol Date: 2017-10-10 Impact factor: 10.864
Authors: Maureen M Leonard; Jocelyn A Silvester; Daniel Leffler; Alessio Fasano; Ciarán P Kelly; Suzanne K Lewis; Jeffrey D Goldsmith; Elliot Greenblatt; William W Kwok; William J McAuliffe; Kevin Galinsky; Jenifer Siegelman; I-Ting Chow; John A Wagner; Anna Sapone; Glennda Smithson Journal: Gastroenterology Date: 2020-10-29 Impact factor: 22.682
Authors: Lotte Smolders; Ronald P Mensink; Mark V Boekschoten; Rogier J J de Ridder; Jogchum Plat Journal: Sci Rep Date: 2018-01-26 Impact factor: 4.379
Authors: Aarón D Ramírez-Sánchez; Ineke L Tan; B C Gonera-de Jong; Marijn C Visschedijk; Iris Jonkers; Sebo Withoff Journal: Int J Mol Sci Date: 2020-11-12 Impact factor: 5.923